Hospital
Ann & Robert H. Lurie Children's Hospital of Chicago
Ann & Robert H. Lurie Children's Hospital of Chicago was paid $7.08M by Medicaid between Jan 2018 and Feb 2022, across 257 billing codes. Its largest line is 97110, Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion — 36% of everything it billed.
33Billing provider infoANN & ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICAGO
CHICAGO, IL 60611
CHICAGO, IL 60611
33aNPI1235234535assigned 09/13/2006
33bProvider typePsychiatric Hospital Unit
28Total paid$7.08M
24GClaims385,503
24DCodes billed257
24AFirst – last monthJan 2018 – Feb 2022
Compared with peers
Next to other Psychiatric Hospital Unit providers in Illinois
Rank by total paid#1 of 24
Median peer was paid$554K
This provider vs. median13×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 113,323 | $2.20M | |
| 2019 | 196,348 | $3.35M | |
| 2020 | 75,387 | $1.51M | |
| 2021 | 253 | $11K | |
| 2022 | 192 | $8K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 36% | 24,097 | 9,439 | $2.55M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 9.4% | 13,648 | 5,600 | $664K |
| 97161 | 8.1% | 4,642 | 3,447 | $571K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 6.3% | 4,581 | 3,339 | $443K |
| 92523 | 2.4% | 1,868 | 1,481 | $171K | |
| 97162 | 2.2% | 1,306 | 1,011 | $157K | |
| 92567 | 2.0% | 9,642 | 6,260 | $140K | |
| 92587 | 1.5% | 6,088 | 4,083 | $104K | |
| L3010 | Foot, insert, removable, molded to patient model, longitudinal arch support, each | 1.4% | 438 | 338 | $101K |
| V5261 | Hearing aid, digital, binaural, bte | 1.4% | 154 | 134 | $96K |
| 94010 | 1.3% | 3,266 | 2,117 | $94K | |
| 92610 | 1.1% | 1,514 | 1,177 | $75K |
245 more codes
| 92579 | <1% | 3,154 | $67K | |
| 92557 | <1% | 1,740 | $62K | |
| 96409 | <1% | 1,263 | $61K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 10,581 | $61K |
| 92582 | <1% | 2,524 | $53K | |
| 80053 | Comprehensive metabolic panel | <1% | 15,843 | $50K |
| V5264 | Ear mold/insert, not disposable, any type | <1% | 1,099 | $46K |
| V5160 | Dispensing fee, binaural | <1% | 143 | $45K |
| 97166 | <1% | 1,247 | $43K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,977 | $43K |
| 72082 | <1% | 1,624 | $40K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 28,699 | $39K |
| 96112 | <1% | 355 | $33K | |
| 83655 | <1% | 3,574 | $33K | |
| L1940 | Ankle foot orthosis, plastic or other material, custom fabricated | <1% | 61 | $30K |
| 87799 | <1% | 1,344 | $28K | |
| 92602 | <1% | 739 | $28K | |
| 92555 | <1% | 1,926 | $28K | |
| 86480 | <1% | 605 | $26K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,175 | $25K |
| 92604 | <1% | 1,003 | $25K | |
| 92595 | <1% | 1,693 | $25K | |
| 73610 | <1% | 1,504 | $24K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 469 | $24K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,069 | $24K |
| 84403 | <1% | 1,861 | $23K | |
| 83970 | <1% | 1,974 | $23K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,185 | $23K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 362 | $22K |
| 94060 | <1% | 559 | $22K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,287 | $21K |
| V5266 | Battery for use in hearing device | <1% | 1,191 | $20K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 755 | $20K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,052 | $20K |
| 97165 | <1% | 452 | $19K | |
| 84439 | <1% | 10,477 | $19K | |
| 73080 | <1% | 1,627 | $19K | |
| 83516 | <1% | 2,939 | $19K | |
| 77072 | <1% | 1,847 | $18K | |
| 73110 | <1% | 1,409 | $17K | |
| 84305 | <1% | 1,606 | $16K | |
| 92556 | <1% | 1,063 | $15K | |
| 73090 | <1% | 1,509 | $15K | |
| 82784 | <1% | 3,243 | $14K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 6,890 | $14K |
| 92594 | <1% | 970 | $14K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 767 | $14K |
| 72081 | <1% | 971 | $13K | |
| 92550 | <1% | 1,069 | $13K | |
| 73590 | <1% | 1,061 | $12K | |
| 82330 | <1% | 3,330 | $12K | |
| 86160 | <1% | 1,704 | $11K | |
| 86008 | <1% | 3,691 | $11K | |
| 92611 | <1% | 298 | $11K | |
| 72170 | <1% | 1,534 | $10K | |
| 86003 | <1% | 2,363 | $10K | |
| 73630 | <1% | 908 | $10K | |
| 80076 | <1% | 4,554 | $9K | |
| 92250 | <1% | 462 | $9K | |
| 74018 | <1% | 893 | $9K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 252 | $9K |
| 80069 | <1% | 4,112 | $8K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,924 | $8K |
| 80061 | Lipid panel | <1% | 5,661 | $8K |
| 92593 | <1% | 629 | $8K | |
| 73140 | <1% | 1,009 | $8K | |
| 96411 | <1% | 213 | $7K | |
| 80197 | <1% | 2,375 | $7K | |
| 83735 | <1% | 5,948 | $7K | |
| 0071A | <1% | 158 | $7K | |
| 77073 | <1% | 339 | $7K | |
| 83520 | <1% | 749 | $7K | |
| 87497 | <1% | 521 | $6K | |
| 96450 | <1% | 112 | $6K | |
| 86162 | <1% | 1,021 | $6K | |
| 0072A | <1% | 141 | $6K | |
| 82570 | <1% | 4,802 | $6K | |
| J9370 | Vincristine sulfate, 1 mg | <1% | 788 | $6K |
| 86038 | <1% | 1,300 | $6K | |
| 83001 | <1% | 1,446 | $6K | |
| 92583 | <1% | 384 | $6K | |
| 81228 | <1% | 251 | $5K | |
| 82157 | <1% | 656 | $5K | |
| 82670 | <1% | 1,138 | $5K | |
| 82610 | <1% | 2,497 | $5K | |
| 73130 | <1% | 504 | $5K | |
| 87186 | <1% | 1,191 | $5K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,345 | $5K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,175 | $5K |
| 73100 | <1% | 401 | $5K | |
| 86140 | <1% | 4,609 | $4K | |
| 82728 | <1% | 3,033 | $4K | |
| 73562 | <1% | 440 | $4K | |
| 84402 | <1% | 778 | $4K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 12,361 | $4K |
| 86800 | <1% | 1,383 | $4K | |
| L1960 | Ankle foot orthosis, posterior solid ankle, plastic, custom fabricated | <1% | 24 | $4K |
| 74230 | <1% | 311 | $4K | |
| 92524 | <1% | 88 | $4K | |
| 84100 | <1% | 5,193 | $4K | |
| 83550 | <1% | 1,839 | $4K | |
| 73560 | <1% | 343 | $4K | |
| 73070 | <1% | 333 | $4K | |
| 86376 | <1% | 1,792 | $3K | |
| 80074 | <1% | 247 | $3K | |
| 86255 | <1% | 1,116 | $3K | |
| 96113 | <1% | 85 | $3K | |
| 82397 | <1% | 1,163 | $3K | |
| 83020 | <1% | 1,077 | $3K | |
| 84146 | <1% | 915 | $3K | |
| 86256 | <1% | 816 | $3K | |
| 82533 | <1% | 791 | $3K | |
| 88185 | <1% | 1,013 | $3K | |
| 85730 | <1% | 2,512 | $3K | |
| 85652 | <1% | 5,594 | $3K | |
| 0001A | <1% | 68 | $3K | |
| 81001 | <1% | 4,793 | $3K | |
| 83002 | <1% | 1,586 | $3K | |
| 94726 | <1% | 305 | $3K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 236 | $3K |
| 85610 | <1% | 3,371 | $3K | |
| 92552 | <1% | 187 | $3K | |
| 73552 | <1% | 206 | $3K | |
| 86225 | <1% | 1,073 | $3K | |
| 86317 | <1% | 28 | $3K | |
| 84480 | <1% | 1,287 | $3K | |
| 86355 | <1% | 271 | $3K | |
| 83498 | <1% | 919 | $2K | |
| 86357 | <1% | 273 | $2K | |
| 85045 | <1% | 4,667 | $2K | |
| 82785 | <1% | 1,504 | $2K | |
| 83540 | <1% | 2,095 | $2K | |
| 87536 | <1% | 58 | $2K | |
| 84030 | <1% | 819 | $2K | |
| 85027 | <1% | 1,699 | $2K | |
| 82627 | <1% | 927 | $2K | |
| 82550 | <1% | 1,629 | $2K | |
| J9260 | Injection, methotrexate sodium, 50 mg | <1% | 270 | $2K |
| 81003 | <1% | 3,968 | $2K | |
| 0004A | <1% | 46 | $2K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 42 | $2K |
| 92083 | <1% | 91 | $2K | |
| 92626 | <1% | 80 | $2K | |
| 82977 | <1% | 1,872 | $2K | |
| 87070 | <1% | 1,419 | $2K | |
| 97163 | <1% | 13 | $2K | |
| 96376 | <1% | 34 | $2K | |
| 84156 | <1% | 3,947 | $2K | |
| 86235 | <1% | 124 | $2K | |
| 83525 | <1% | 855 | $2K | |
| 96415 | <1% | 57 | $2K | |
| 70370 | <1% | 116 | $1K | |
| 73000 | <1% | 183 | $1K | |
| 86885 | <1% | 964 | $1K | |
| 84460 | <1% | 1,244 | $1K | |
| 83615 | <1% | 1,080 | $1K | |
| 87631 | <1% | 26 | $1K | |
| 87077 | <1% | 807 | $1K | |
| 80299 | <1% | 18 | $1K | |
| 83993 | <1% | 155 | $1K | |
| 88184 | <1% | 1,234 | $1K | |
| 82379 | <1% | 279 | $1K | |
| 92060 | <1% | 127 | $1K | |
| 82390 | <1% | 232 | $1K | |
| 82652 | <1% | 89 | $1K | |
| 84238 | <1% | 55 | $978.21 | |
| 82139 | <1% | 251 | $972.48 | |
| 84244 | <1% | 57 | $964.30 | |
| 82565 | <1% | 719 | $941.34 | |
| 92522 | <1% | 29 | $938.00 | |
| 82542 | <1% | 99 | $910.99 | |
| 0002A | <1% | 20 | $849.49 | |
| 87493 | <1% | 40 | $842.00 | |
| 95012 | <1% | 518 | $798.27 | |
| 82043 | <1% | 1,178 | $758.12 | |
| 86901 | <1% | 880 | $726.23 | |
| 85246 | <1% | 439 | $714.00 | |
| 73060 | <1% | 80 | $711.63 | |
| 94760 | <1% | 1,150 | $679.76 | |
| 80195 | <1% | 326 | $668.94 | |
| 82103 | <1% | 266 | $649.41 | |
| 89051 | <1% | 272 | $629.40 | |
| 80164 | <1% | 286 | $618.15 | |
| 86146 | <1% | 21 | $552.50 | |
| 92586 | <1% | 13 | $546.43 | |
| 86360 | <1% | 371 | $531.37 | |
| 86592 | <1% | 690 | $527.86 | |
| 92592 | <1% | 37 | $526.27 | |
| 82607 | <1% | 76 | $525.99 | |
| 86900 | <1% | 880 | $502.98 | |
| 82248 | <1% | 536 | $456.59 | |
| 82947 | <1% | 717 | $455.95 | |
| 73620 | <1% | 35 | $445.99 | |
| 86359 | <1% | 382 | $429.95 | |
| 83021 | <1% | 37 | $401.38 | |
| 93296 | <1% | 21 | $400.88 | |
| 83880 | <1% | 123 | $390.61 | |
| 83519 | <1% | 49 | $373.43 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 262 | $369.75 |
| 82105 | <1% | 71 | $342.98 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 27 | $324.55 |
| 83690 | <1% | 167 | $306.69 | |
| 87102 | <1% | 112 | $301.93 | |
| 86774 | <1% | 71 | $271.82 | |
| 87205 | <1% | 491 | $259.54 | |
| 84446 | <1% | 76 | $242.92 | |
| 85247 | <1% | 17 | $221.42 | |
| 72040 | <1% | 17 | $203.96 | |
| 84520 | <1% | 224 | $188.73 | |
| 84450 | <1% | 204 | $186.38 | |
| 87338 | <1% | 19 | $178.27 | |
| 85240 | <1% | 88 | $165.77 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 280 | $163.06 |
| 84550 | <1% | 178 | $161.82 | |
| 84300 | <1% | 226 | $139.39 | |
| 82017 | <1% | 29 | $128.03 | |
| 86147 | <1% | 24 | $125.85 | |
| 85576 | <1% | 60 | $110.95 | |
| 84133 | <1% | 183 | $106.91 | |
| 82436 | <1% | 163 | $100.74 | |
| 86706 | <1% | 24 | $74.92 | |
| J9209 | Injection, mesna, 200 mg | <1% | 41 | $68.11 |
| 97803 | <1% | 16 | $65.00 | |
| 81025 | <1% | 80 | $53.24 | |
| 82150 | <1% | 30 | $51.88 | |
| 87427 | <1% | 35 | $50.28 | |
| 85245 | <1% | 37 | $47.63 | |
| 86430 | <1% | 25 | $45.98 | |
| 84590 | <1% | 78 | $42.44 | |
| 85384 | <1% | 38 | $42.02 | |
| 85613 | <1% | 30 | $31.39 | |
| 86880 | <1% | 18 | $31.38 | |
| 82085 | <1% | 26 | $31.26 | |
| 87045 | <1% | 35 | $31.18 | |
| 83605 | <1% | 23 | $30.92 | |
| 82310 | <1% | 36 | $25.61 | |
| 82247 | <1% | 44 | $25.41 | |
| 82140 | <1% | 21 | $21.69 | |
| 87046 | <1% | 35 | $19.24 | |
| 85378 | <1% | 16 | $17.68 | |
| 82465 | <1% | 24 | $8.57 | |
| 84478 | <1% | 20 | $2.85 | |
| 86923 | 0% | 13 | $0.00 | |
| 36591 | 0% | 220 | $0.00 | |
| 80050 | General health panel | 0% | 107 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMILLER, ALEX (SVP AND CHIEF FINANCIAL OFFICER)